Sandoz
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Sandoz sits in the top decile of US sponsors by registered trial count (#553 of 15,742 sponsors by registered trial count).
Sandoz: 29 sponsored US clinical trials, 1 recruiting.
Sandoz sponsors 29 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 27 completed. 14 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cytopenias, with 2 trials.
Top-decile sponsor footprint
Sandoz ranks in the top decile of sponsors by registered trial count (#553 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
27 of 27 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
29 total, page 1 of 1
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
NCT06847724
A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma
NCT06153238
A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
NCT06159790
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit
NCT05282004
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe
NCT05161806
Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration
NCT04864834
Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis
NCT03974100
This Was a Clinical Study Investigating the Moisturization and Desquamation Effect of AmLactin® Rapid Relief Restoring Lotion + Ceramides on Dry Skin in Healthy Female Volunteers. AmLactin® Rapid Relief is an Over-the-counter Cosmetic
NCT04085809
A Study Comparing Two Ferric Carboxymaltose Formulations in Patients With Iron Deficiency Anemia
NCT03399084
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
NCT02744755
GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®
NCT02514772
Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis
NCT02638259
Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira
NCT02016105
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
NCT01693029
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
NCT01516736
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
NCT01274182
A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis
NCT01279057
A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis
NCT01038427
Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair
NCT00927758
A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to Azidothymidine
NCT00002263
A Phase I/II Pilot Study of Simultaneously Administered Rhu GM-CSF ( CHO Cell ) and Azidothymidine ( AZT ) in Patients With Severe HIV Infection and Leukopenia: Pharmacokinetics and Feasibility
NCT00002006
A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis
NCT00002016
A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea
NCT00002252
A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia
NCT00002007
A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.
NCT00002253
A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria
NCT00002268
A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia
NCT00002258
An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia
NCT00002008
A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia
NCT00002009
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 1 |
| Phase 3 | 14 |
What is open in the Sandoz pipeline
1 recruiting of 29 indexed (3% open); 27 completed (93%).
Phase mix: 14 late (III/IV) vs 10 early (I/II) (balanced across stages).
Top condition: Cytopenias (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sandoz: open-pipeline peers nationwide
Peers matched on 29 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Sandoz sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 29 trials (± recruiting share)
- BeOne Medicines · 29 trials · 79% recruiting
- BioCryst Pharmaceuticals · 29 trials · 7% recruiting
- California Pacific Medical Center Research Institute · 29 trials · 10% recruiting
- Center for International Blood and Marrow Transplant Research · 29 trials · 24% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Medtronic MiniMed · 3% recruiting · 29 trials
- Sonova · 3% recruiting · 29 trials
- USDA Beltsville Human Nutrition Research Center · 3% recruiting · 29 trials
- SCRI Development Innovations · 3% recruiting · 146 trials
Related
What to do with this Sandoz page
29 registered trials is a research-attention snapshot, not an endorsement of Sandoz or any single study.
- 1 of Sandoz's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cytopenias is the condition Sandoz studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cytopenias trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Sandoz pipeline card: 29 registered trials from official public datasets.Report a data error.